Research programme: extended-release therapeutics - Pacira Pharmaceuticals

Next Previous
Drug Profile

Research programme: extended-release therapeutics - Pacira Pharmaceuticals

Alternative Names: DepoMeloxicam; DepoMLX; DepoNSAID

Latest Information Update: 23 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pacira Pharmaceuticals
  • Class Cyclohexanecarboxylic acids; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Acute pain

Most Recent Events

  • 28 Feb 2018 DepoMeloxicam is still in preclinical development for acute pain in USA
  • 28 Feb 2018 Pacira Pharmaceuticals has patents pending for DepoMeloxicam
  • 28 Feb 2018 Pacira Pharmaceuticals receives patent allowance for DepoMeloxicam in USA before February 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top